Medically Reviewed Content
Written by Rob Anderson, Health Technology Researcher & Medical Content Specialist. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting any medication.
Two of the most talked-about weight loss medications right now are Mounjaro (tirzepatide) and Wegovy (semaglutide). Both are GLP-1 receptor agonists, but Mounjaro has an additional mechanism that may make it more effective. Here’s what the clinical data shows.
The Clinical Trial Numbers
In the landmark SURMOUNT-1 trial, Mounjaro (tirzepatide 15mg) produced an average weight loss of 22.5% of body weight over 72 weeks. The STEP 1 trial for Wegovy (semaglutide 2.4mg) showed an average weight loss of 14.9% over 68 weeks.
In head-to-head studies, tirzepatide consistently outperforms semaglutide for weight loss outcomes.
Why Mounjaro May Be More Effective
While Wegovy activates only GLP-1 receptors, Mounjaro is a “dual agonist” that activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual action appears to produce synergistic effects on appetite suppression and metabolism, leading to greater weight loss.
Side Effect Comparison
Both medications share similar side effect profiles, primarily gastrointestinal. Nausea, diarrhea, vomiting, and constipation are the most common effects for both. Studies suggest tirzepatide may have slightly higher rates of GI side effects, particularly at higher doses.
Cost and Access
Both medications have a list price of approximately $900-$1,100 per month without insurance. Wegovy has been available since 2021, while Mounjaro received obesity approval (as Zepbound) in late 2023.
Bottom Line
If maximum weight loss is your goal and you can tolerate the side effects, clinical data suggests Mounjaro/Zepbound may offer greater results. However, individual responses vary, and the best medication for you depends on your health history, other medications, and your doctor’s recommendation.
Always consult your doctor before making any changes to your medication regimen.
Mounjaro vs Wegovy: Full Data Comparison
| Factor | Mounjaro (Tirzepatide) | Wegovy (Semaglutide) |
|---|---|---|
| Mechanism | Dual GIP + GLP-1 agonist | GLP-1 agonist only |
| FDA Approval | Type 2 diabetes (2022) | Chronic weight management (2021) |
| Average Weight Loss | ~20–22% (15mg, SURMOUNT) | ~15–17% (2.4mg, STEP 1) |
| Max Weekly Dose | 15 mg | 2.4 mg |
| Head-to-Head (SURMOUNT-5) | Won — 20.2% vs 13.7% | Lost — 13.7% vs 20.2% |
| Monthly List Price | ~$1,069 | ~$1,349 |
| Sleep Apnea Approval | Yes (Zepbound formulation) | No |
| CV Approval | CV trial ongoing | Yes — SELECT trial (2024) |
SURMOUNT-5: The Head-to-Head Trial
For years, comparing Mounjaro and Wegovy meant looking at separate trials with different patient populations. In 2024, the SURMOUNT-5 trial changed that by directly pitting tirzepatide against semaglutide in the same study.
The result: patients on tirzepatide 15 mg lost an average of 20.2% of body weight, compared to 13.7% for those on semaglutide 2.4 mg — a 47% relative difference. Tirzepatide won decisively for weight loss.
However, the SURMOUNT-5 comparison was Mounjaro at max dose vs Wegovy at max dose. Not all patients can tolerate or are prescribed max doses.
Where Wegovy Still Has the Edge
Tirzepatide wins on raw weight loss, but Wegovy has meaningful advantages:
- Proven cardiovascular benefit — The SELECT trial (2024) confirmed Wegovy reduces major CV events by 20% in non-diabetic obese adults. This earned Wegovy FDA approval for CV risk reduction and expanded Medicare coverage.
- More long-term safety data — Wegovy has been on market longer; more real-world data accumulated
- Better insurance coverage for obesity — Wegovy’s CV approval has driven coverage expansion; Zepbound/Mounjaro coverage is still catching up
- Lower list price — Wegovy at ~$1,349/mo vs Mounjaro at ~$1,069/mo — actually Mounjaro is cheaper now
Cost Comparison: Mounjaro vs Wegovy
Mounjaro is actually cheaper at list price (~$1,069/mo vs ~$1,349/mo). But real out-of-pocket cost depends on insurance:
- Both offer manufacturer savings cards that can bring cost to $25/mo for eligible commercially insured patients
- Zepbound vials (tirzepatide without the auto-injector) are available through LillyDirect at $399–$549/month for self-pay patients — significantly cheaper
- Medicare coverage of Wegovy expanded after SELECT trial; Zepbound Medicare coverage is more limited
Which Should You Choose?
Choose Mounjaro/Zepbound if: You want maximum weight loss, have Type 2 diabetes with poorly controlled blood sugar, also have sleep apnea, or price is a concern (Zepbound vials are the most affordable brand-name option). For more details, see our Eli Lilly savings programs.
Choose Wegovy if: You have obesity plus cardiovascular disease (approved for CV risk reduction), your insurer covers Wegovy but not Zepbound, or you haven’t responded well to tirzepatide.
Frequently Asked Questions
Is Mounjaro approved for weight loss?
Not directly — Mounjaro is FDA-approved for Type 2 diabetes. Zepbound (same tirzepatide molecule, different brand) is FDA-approved for chronic weight management. Many insurance plans only cover Mounjaro for T2D, while Zepbound is required for the obesity indication.
Can you switch from Wegovy to Mounjaro?
Yes. Switching between GLP-1s is common. Since they’re different molecules with different mechanisms, there’s no direct dose equivalency — your doctor will typically start Mounjaro at 2.5 mg and titrate up, regardless of your previous Wegovy dose.
Why does tirzepatide cause more weight loss than semaglutide?
Tirzepatide activates both GIP and GLP-1 receptors simultaneously. The dual mechanism appears to produce stronger appetite suppression and metabolic effects than GLP-1 alone. GIP receptors in fat tissue may also play a role in fat metabolism that semaglutide doesn’t directly address.
📚 Related Reading
📖 Further Reading
Considering GLP-1 Medication?
Check eligibility for compounded semaglutide — the affordable alternative to brand-name Ozempic starting from $149/month. No insurance required.
Take the Free Eligibility Quiz →
Sponsored | Affiliate link | Not available in all states
Sources & References
- U.S. Food and Drug Administration (FDA) – Drug Approvals and Databases
- National Institutes of Health (NIH) – PubMed Medical Literature
- American Diabetes Association – Medication & Therapies
- Novo Nordisk – Clinical Research Data
- Eli Lilly – Medical Information
This content is regularly reviewed and updated to reflect the latest medical research and FDA guidance.